Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …

Objective To investigate the efficacy and safety of etanercept (ETN) in paediatric subjects
with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA)…

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with
extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), …

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry - PMC Back to Top Skip
to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

Biologicals are very effective for inhibiting disease progression in active juvenile idiopathic
arthritis (JIA). To date, there have been no recommendations on how and when to stop …

Objectives CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER
study on the safety and efficacy of etanercept in patients with JIA, categorized as extended …

… Nadina Rubio-Pérez, Sheila Oliveira, Katarzyna Kobusinska, Heinrike Schmeling, Flavio
Sztajnbok, Frank Weller… K. Kobusinska reports other funding from F. Hoffmann-La Roche Ltd. H. …

Conclusions IgG4-RD is a poorly recognised disease, especially in the paediatric population.
To the best of our knowledge, case reports on IgG4-RD in paediatric patients available in …

Background/Purpose: The phase 3 CHERISH trial demonstrated the efficacy of tocilizumab (TCZ),
an interleukin‐6 receptor inhibitor, in patients with polyarticular‐course juvenile …

Background CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year
CLIPPER study of the safety and efficacy of etanercept (ETN) in the treatment of …